Literature DB >> 28835489

Epstein-Barr Virus LMP1-Mediated Oncogenicity.

Liang Wei Wang1,2, Sizun Jiang1,2, Benjamin E Gewurz3,2,4.   

Abstract

Epstein-Barr virus latent membrane protein 1 (LMP1) is expressed in multiple human malignancies, including nasopharyngeal carcinoma and Hodgkin and immunosuppression-associated lymphomas. LMP1 mimics CD40 signaling to activate multiple growth and survival pathways, in particular, NF-κB. LMP1 has critical roles in Epstein-Barr virus (EBV)-driven B-cell transformation, and its expression causes fatal lymphoproliferative disease in immunosuppressed mice. Here, we review recent developments in studies of LMP1 signaling, LMP1-induced host dependency factors, mouse models of LMP1 lymphomagenesis, and anti-LMP1 immunotherapy approaches.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  CD40; LMP1; NF-κB; gamma herpesvirus; oncogene; super-enhancer

Mesh：

Substances：

Year:  2017        PMID： 28835489      PMCID： PMC5640852          DOI： 10.1128/JVI.01718-16

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  86 in total

1.  Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy.

Authors:  Corey Smith; Janice Tsang; Leone Beagley; Daniel Chua; Victor Lee; Vivian Li; Denis J Moss; William Coman; Kwok H Chan; John Nicholls; Dora Kwong; Rajiv Khanna
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

2.  The C-terminal activating region 2 of the Epstein-Barr virus-encoded latent membrane protein 1 activates NF-kappaB through TRAF6 and TAK1.

Authors:  Liming Wu; Hiroyasu Nakano; Zhenguo Wu
Journal:  J Biol Chem       Date:  2005-11-08       Impact factor: 5.157

3.  LMP1 protein from the Epstein-Barr virus is a structural CD40 decoy in B lymphocytes for binding to TRAF3.

Authors:  ShuangDing Wu; Ping Xie; Kate Welsh; Chenglong Li; Chao-Zhou Ni; Xiuwen Zhu; John C Reed; Arnold C Satterthwait; Gail A Bishop; Kathryn R Ely
Journal:  J Biol Chem       Date:  2005-07-11       Impact factor: 5.157

4.  Mouse model for acute Epstein-Barr virus infection.

Authors:  Tristan Wirtz; Timm Weber; Sven Kracker; Thomas Sommermann; Klaus Rajewsky; Tomoharu Yasuda
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-16       Impact factor: 11.205

Review 5.  The Latent Membrane Protein 1 (LMP1).

Authors:  Arnd Kieser; Kai R Sterz
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

6.  Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Upregulates Glucose Transporter 1 Transcription via the mTORC1/NF-κB Signaling Pathways.

Authors:  Jun Zhang; Lin Jia; Weitao Lin; Yim Ling Yip; Kwok Wai Lo; Victoria Ming Yi Lau; Dandan Zhu; Chi Man Tsang; Yuan Zhou; Wen Deng; Hong Lok Lung; Maria Li Lung; Lai Man Cheung; Sai Wah Tsao
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

7.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

8.  Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6.

Authors:  Micah Luftig; Efthimios Prinarakis; Teruhito Yasui; Theodore Tsichritzis; Ellen Cahir-McFarland; Jun-Ichiro Inoue; Hiroyasu Nakano; Tak Wah Mak; Wen-Chen Yeh; Xiaoxia Li; Shizuo Akira; Nobutaka Suzuki; Shinobu Suzuki; George Mosialos; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

9.  The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8.

Authors:  Shuvomoy Banerjee; Jie Lu; Qiliang Cai; Abhik Saha; Hem Chandra Jha; Richard Kuo Dzeng; Erle S Robertson
Journal:  PLoS Pathog       Date:  2013-05-02       Impact factor: 6.823

10.  Epstein-Barr virus LMP2A reduces hyperactivation induced by LMP1 to restore normal B cell phenotype in transgenic mice.

Authors:  Alexandra C Vrazo; Maria Chauchard; Nancy Raab-Traub; Richard Longnecker
Journal:  PLoS Pathog       Date:  2012-04-19       Impact factor: 6.823
View more
  41 in total

Review 1.  The molecular march of primary and recurrent nasopharyngeal carcinoma.

Authors:  Nicholas J Campion; Munira Ally; Bernhard J Jank; Jahangir Ahmed; Ghassan Alusi
Journal:  Oncogene       Date:  2021-01-21       Impact factor: 9.867

Review 2.  Herpesvirus latency.

Authors:  Jeffrey I Cohen
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

Review 3.  More than just oncogenes: mechanisms of tumorigenesis by human viruses.

Authors:  Marta M Gaglia; Karl Munger
Journal:  Curr Opin Virol       Date:  2018-09-27       Impact factor: 7.090

4.  Dysregulation of Dual-Specificity Phosphatases by Epstein-Barr Virus LMP1 and Its Impact on Lymphoblastoid Cell Line Survival.

Authors:  Kai-Min Lin; Sue-Jane Lin; Juin-Han Lin; Pei-Yi Lin; Pu-Lin Teng; Hsueh-Erh Wu; Te-Huei Yeh; Ying-Piao Wang; Mei-Ru Chen; Ching-Hwa Tsai
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

5.  The Epstein-Barr Virus Enhancer Interaction Landscapes in Virus-Associated Cancer Cell Lines.

Authors:  Weiyue Ding; Chong Wang; Yohei Narita; Hongbo Wang; Merrin Man Long Leong; Alvin Huang; Yifei Liao; Xuefeng Liu; Yusuke Okuno; Hiroshi Kimura; Benjamin Gewurz; Mingxian Teng; Shuilin Jin; Yoshitaka Sato; Bo Zhao
Journal:  J Virol       Date:  2022-09-12       Impact factor: 6.549

Review 6.  Molecular mechanisms of viral oncogenesis in humans.

Authors:  Nathan A Krump; Jianxin You
Journal:  Nat Rev Microbiol       Date:  2018-11       Impact factor: 60.633

Review 7.  Oncogenic spiral by infectious pathogens: Cooperation of multiple factors in cancer development.

Authors:  Jun-Ichirou Yasunaga; Masao Matsuoka
Journal:  Cancer Sci       Date:  2017-12-03       Impact factor: 6.716

8.  LIMD1 is induced by and required for LMP1 signaling, and protects EBV-transformed cells from DNA damage-induced cell death.

Authors:  Ling Wang; Mary E A Howell; Brooke McPeak; Katrina Riggs; Carissa Kohne; Jether Uel Yohanon; Daniel E Foxler; Tyson V Sharp; Jonathan P Moorman; Zhi Q Yao; Shunbin Ning
Journal:  Oncotarget       Date:  2017-12-26

Review 9.  Meet the Insidious Players: Review of Viral Infections in Head and Neck Cancer Etiology with an Update on Clinical Trials.

Authors:  Lejla Mahmutović; Esma Bilajac; Altijana Hromić-Jahjefendić
Journal:  Microorganisms       Date:  2021-05-06

10.  Upregulation of the Chemokine Receptor CCR2B in Epstein‒Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program.

Authors:  Svetlana Kozireva; Zhanna Rudevica; Mikhail Baryshev; Ainars Leonciks; Elena Kashuba; Irina Kholodnyuk
Journal:  Viruses       Date:  2018-05-03       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.